Justin Matulay, MD
Urology · Charlotte, NCNPI 1295008324
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,840 of the $4,989 with a category attached, or 77.0%. 7 manufacturers reported payments, led by Sanofi at 56.9% of the total. Reporting peaked in 2022 at $4,096 and has fallen 95.3% since, to $194 in 2024.
Across 19 payments — averaging $262.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$3K
- E.r. Squibb & Sons, L.L.C.$1K
- Urogen Pharma, Inc.$704
- Boston Scientific$287
- Photocure Inc$73
- Merck$44
- plus $41 from 1 others
Across 15 payments — averaging $9664.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$145K
What the payments were for
- Consulting fees$3,84077%
- Food & beverage$1,14923%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 1 | $2,840 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,000 |
| Urogen Pharma, Inc. | 9 | $704 |
| Boston Scientific | 5 | $287 |
| Photocure Inc | 1 | $73 |
| Merck | 1 | $44 |
| Johnson & Johnson | 1 | $41 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JELMYTO$571
How this compares
$4,989 in reported general payments places this provider in the 65th percentile of 434 urology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 16 | $16,703 |
| Oxybutynin Chloride ErOxybutynin Chloride | 114 | $1,699 |
| Trospium Chloride | 17 | $1,225 |
| Tamsulosin Hcl | 93 | $1,103 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 32 | $298 |
| Finasteride | 11 | $156 |
| Ciprofloxacin Hcl | 15 | $108 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $57 |
| Cephalexin | 11 | $40 |
Paid to pharmacies, not to this prescriber.
Other urology in Charlotte
- Michael KennellyCharlotte$1.3M
- Manish PatelCharlotte$84K
- Kris GastonCharlotte$32K
- Todd CohenCharlotte$18K
- Ornob RoyCharlotte$17K
- Maxim McKibbenCharlotte$15K
- Robert LippittSmithfield$11.4M
- John KasparRaleigh$1.1M
- Judd MoulDurham$1M
- Daniel GeorgeDurham$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.